Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Rilpivirine Once Daily over 14 days following Drug Intake Cessation in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2015
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Jun 2013 Additional lead trial centre identified as reported by United Kingdom Clinical Research Network.
- 05 Jun 2013 Accrual to date is 125% according to United Kingdom Clinical Research Network.